Edition:
United Kingdom

Astellas Pharma Inc (4503.T)

4503.T on Tokyo Stock Exchange

1,416JPY
22 Nov 2017
Change (% chg)

¥-21 (-1.46%)
Prev Close
¥1,438
Open
¥1,436
Day's High
¥1,437
Day's Low
¥1,416
Volume
7,968,500
Avg. Vol
7,387,625
52-wk High
¥1,688
52-wk Low
¥1,332

Latest Key Developments (Source: Significant Developments)

Seattle Genetics, Astellas initiate phase 1b trial for Enfortumab Vedotin
Wednesday, 8 Nov 2017 

Nov 8 (Reuters) - Seattle Genetics Inc :Seattle Genetics and Astellas initiate phase 1B trial of Enfortumab Vedotin in combination with immune checkpoint inhibitor therapies in locally advanced or metastatic urothelial cancer.Primary objective of trial is to assess safety and tolerability of Enfortumab Vedotin in combination with CPI therapy​.  Full Article

Astellas Pharma completes share repurchase
Wednesday, 1 Nov 2017 

Nov 1 (Reuters) - Astellas Pharma Inc <4503.T>:Says it completed repurchase of 49.3 million shares of its common stock, for 70 billion yen in total, as of Oct. 31 .  Full Article

FDA grants fast track status to Astellas for acute myeloid leukemia drug
Wednesday, 11 Oct 2017 

Oct 10 (Reuters) - Astellas Pharma Inc <4503.T>-:U.S. FDA grants fast track designation to Astellas for development of gilteritinib in relapsed or refractory acute myeloid leukemia.  Full Article

Seattle Genetics and Astellas initiate pivotal trial of enfortumab vedotin
Tuesday, 10 Oct 2017 

Oct 10 (Reuters) - Astellas Pharma Inc <4503.T>::Seattle Genetics and Astellas initiate pivotal trial of enfortumab vedotin for patients with locally advanced or metastatic urothelial cancer.Seattle Genetics Inc - ‍companies also plan to initiate a combination trial of enfortumab vedotin with CPI therapy in late 2017​.  Full Article

Astellas Pharma to repurchase shares
Friday, 28 Jul 2017 

July 28(Reuters) - Astellas Pharma Inc <4503.T>:Says it will repurchase up to 50 million shares, representing 2.4 percent of outstanding.Says share repurchase price up to 70 billion yen in total.Says repurchase period from July 31 to Oct. 31.  Full Article

Astellas Pharma files lawsuit against patent infringement of Myrbetriq® in U.S.
Friday, 7 Oct 2016 

Astellas Pharma Inc <4503.T>:Says the co and its subsidiaries jointly filed a lawsuit with the United States District Court against Actavis Elizabeth LLC and its affiliates, who filed an abbreviated new drug application for a generic version of Astellas’ mirabegron (generic name) product sold under the trademark Myrbetriq® in the U.S..  Full Article

Astellas Pharma gets approval for medicine for hyperphosphatemia in Japan
Wednesday, 28 Sep 2016 

Astellas Pharma Inc <4503.T>:Says the co received a marketing approval of Kiklin® Granules 86.2% for the indication of treatment of hyperphosphatemia in patients with chronic kidney disease in Japan.  Full Article

Astellas Pharma to create companion diagnostic for acute Myeloid Leukemia treatment-Nikkei<4503.T>
Monday, 15 Aug 2016 

Nikkei: Astellas Pharma to create with U.S. co so-called companion diagnostic for acute myeloid leukemia treatment the co has been working on-Nikkei . Astellas Pharma seeks to obtain approval in Japan, U.S. and elsewhere within three years-Nikkei .  Full Article

Astellas Pharma submits new drug application for extended-release tablets of quetiapine fumarate in Japan
Tuesday, 9 Aug 2016 

Astellas Pharma Inc <4503.T>: Says it submitted a new drug application to the Ministry of Health, Labour and Welfare in Japan for extended-release tablets of quetiapine fumarate for the indication of improvement of depressive symptoms associated with bipolar disorder .Says it has a license agreement with AstraZeneca UK Ltd. that provides the co exclusive rights to develop and commercialize extended-release tablets of quetiapine fumarate in Japan.  Full Article

Proteostasis Therapeutics achieves preclinical milestone in Astellas Pharma collaboration
Monday, 8 Aug 2016 

Proteostasis Therapeutics Inc : Proteostasis Therapeutics achieves preclinical milestone in Astellas Pharma collaboration . Says milestone demonstrated selective modulation of UPR pathway in vitro . Says milestone triggered an undisclosed payment from Astellas . Astellas retains right to begin 2 additional projects, which, if fully exercised would bring potential value of collaboration to $1.2 billion .As a result of preclinical milestone, co eligible for further milestone payments, which could result in total payments of over $400 million.  Full Article

UPDATE 4-Cytokinetics sinks on abandoning ALS drug after failed trial

Nov 21 Cytokinetics Inc shares plummeted nearly 28 percent on Tuesday after the drugmaker said it would stop developing one of its treatments for ALS, a fatal neuro-degenerative disorder, after the drug failed to improve lung function in a key trial.